FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Expires: January 31, 2005 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *   ALTA BIOPHARMA PARTNERS II LP 2. Date of Event Requiring Statement (Month/Day/Year) 08/17/2007 3. Issuer Name and Ticker or Trading Symbol CORCEPT THERAPEUTICS INC [CORT] (Last) (First) (Middle) ONE EMBARCADERO CENTER, SUITE 3700 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director __X__ 10% Owner _____ Officer (give title below) _____ Other (specify below) 5. If Amendment, Date Original Filed(Month/Day/Year) (Street) SAN FRANCISCO, CA 94111 6. Individual or Joint/Group Filing(Check Applicable Line) ___ Form filed by One Reporting Person _X_ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5) Common Stock 4,150,655 (1) I See footnotes (1) (2)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
ALTA BIOPHARMA PARTNERS II LP ONE EMBARCADERO CENTER SUITE 3700 SAN FRANCISCO, CA 94111	Â	  X	Â	Â
ALTA BIOPHARMA MANAGEMENT II LLC ONE EMBARCADERO CENTER SUITE 3700 SAN FRANCISCO, CA 94111	Â	  X	Â	Â
ALTA EMBARCADERO BIOPHARMA PARTNERS II LLC ONE EMBARCADERO CENTER SUITE 3700 SAN FRANCISCO, CA 94111	Â	  X	Â	Â
DELEAGE JEAN ONE EMBARCADERO CENTER SUITE 3700 SAN FRANCISCO, CA 94111	Â	  X	Â	Â
CHAMPSI FARAH ONE EMBARCADERO CENTER SUITE 3700 SAN FRANCISCO, CA 94111	Â	  X	Â	Â
ALTA PARTNERS II INC ONE EMBARCADERO CENTER SUITE 3700 SAN FRANCISCO, CA 94111	Â	  X	Â	Â

Signatures

Alix Marduel, Managing Director		08/20/2004
**Signature of Reporting Person		Date
Alix Marduel, Managing Director		08/20/2007
**Signature of Reporting Person		Date
Alix Marduel, Manager		08/20/2007
**Signature of Reporting Person		Date
Jean Deleage		08/20/2007
**Signature of Reporting Person		Date
Farah Champsi		08/20/2007
**Signature of Reporting Person		Date
Jean Deleage, President		08/20/2007
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	Alta Partners II, Inc. ("APII") provides investment advisory services to several venture capital funds including Alta BioPharma Partners II, L.P. ("ABPII") & Alta Embarcadero BioPharma Partners II, LLC ("AEBPII"). On 8/17/07, ABPII purchased 918,589 shares ("sh")of Common Stock ("Cm")& AEBPII purchased 33,792 sh Cm from the Company at $2.10 per share, in conjunction with the Common Stock Purchase Agreement dated 8/17/07. The purchase of this stock resulted in the funds affiliated with APII becoming 10% Owners. ABPII now benefically owns 3,997,378 sh Cm & AEBPII beneficially owns 153,277 sh Cm.
(2)	Jean Deleage, Alix Marduel and Farah Champsi (collectively known as "the principals") are managing directors of Alta BioPharma Management II, LLC (which is the general partner of Alta BioPharma Partners II, L.P.)and managers of AEBPII. As managing directors and managers they may be deemed to share voting & investment powers over the shares held by the funds. The principals of Alta Partners II, Inc. disclaim beneficial ownership of all such shares held by the foregoing funds, except to the extent of their proportionate pecuniary interests therein.
  Remarks: Cross-reference with Form 4 filed dated 8/17/2007 filed on behalf of Alix Marduel, Director of Corcept Therapeutics, Inc. on 8/20/2007.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.